Cybin (CYBN) News Today $11.14 +0.13 (+1.18%) (As of 11/20/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Cybin's (CYBN) "Buy" Rating Reiterated at HC WainwrightNovember 21 at 3:01 AM | americanbankingnews.comOptimistic Buy Rating for Cybin: Promising CYB003 Phase 2 Results and Market PotentialNovember 19 at 9:14 PM | markets.businessinsider.comCybin’s CYB003: Promising Clinical Trial Results Lead to Buy RatingNovember 19 at 9:14 PM | markets.businessinsider.comCybin Reports Positive Phase 2 Data for CYB003, Demonstrating Breakthrough 12-Month Efficacy in Treating Major Depressive DisorderNovember 18 at 9:47 PM | theglobeandmail.comCybin Stock In Focus On MDD Treatment's 'Breakthrough’ Efficacy: Retail Turns Extremely BullishNovember 18 at 4:45 PM | msn.comCybin’s CYB003: Promising Efficacy in MDD and Strong Buy Rating ReaffirmedNovember 18 at 4:45 PM | markets.businessinsider.comCybin: CYB003 data demonstres ‘breakthrough 12-month efficacy’ in MDD treatmentNovember 18 at 4:45 PM | markets.businessinsider.comCybin (NYSE:CYBN) Earns Buy Rating from HC WainwrightHC Wainwright restated a "buy" rating and issued a $190.00 price objective on shares of Cybin in a research report on Monday.November 18 at 12:42 PM | marketbeat.comCybin Initiates PARADIGM: A Multinational Pivotal Phase 3 Program Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder and Reports Second Quarter ...November 14, 2024 | businesswire.comCanaccord Genuity Group Lowers Cybin (NYSE:CYBN) Price Target to $86.00Canaccord Genuity Group dropped their price objective on shares of Cybin from $96.00 to $86.00 and set a "buy" rating for the company in a report on Thursday.November 14, 2024 | marketbeat.comCybin to Present 12-Month Phase 2 Data for CYB003 in Major Depressive Disorder on November 18, 2024November 14, 2024 | businesswire.comCybin (AMEX:CYBN) Stock Quotes, Forecast and News SummaryNovember 14, 2024 | benzinga.comCybin’s Phase 3 Trials and Financial UpdateNovember 13, 2024 | markets.businessinsider.comCybin launches new program phase to treat major depressive disorderNovember 13, 2024 | msn.comCybin Inc. Begins Phase 3 Trials, Betting Big On CYB003 To Treat DepressionNovember 13, 2024 | benzinga.comCybin Initiates PARADIGM: A Multinational Pivotal Phase 3 Program Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder and Reports Second Quarter Financial ResultsNovember 13, 2024 | businesswire.comCybin Inc. (NYSE:CYBN) is Rosalind Advisors Inc.'s 6th Largest PositionRosalind Advisors Inc. trimmed its holdings in Cybin Inc. (NYSE:CYBN - Free Report) by 94.4% in the third quarter, according to the company in its most recent filing with the SEC. The fund owned 1,075,105 shares of the company's stock after selling 18,224,895 shares during the quarter. Cybin accounNovember 6, 2024 | marketbeat.comCybin’s Promising Growth in the Psychedelic Sector Justifies Buy RatingNovember 4, 2024 | markets.businessinsider.comPDS Planning Inc Has $2.38 Million Stock Holdings in Cybin Inc. (NYSE:CYBN)PDS Planning Inc reduced its holdings in shares of Cybin Inc. (NYSE:CYBN - Free Report) by 76.8% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 267,580 shares of the company's stock after selling 885,540 shares during tNovember 4, 2024 | marketbeat.comCybin to Highlight Innovations at Health SummitOctober 31, 2024 | markets.businessinsider.comCybin Announces Grant of First U.S. Composition of Matter Patent in Support of its CYB005 Phenethylamines ProgramOctober 24, 2024 | businesswire.comSanctuary Advisors LLC Makes New Investment in Cybin Inc. (NYSE:CYBN)Sanctuary Advisors LLC bought a new stake in Cybin Inc. (NYSE:CYBN - Free Report) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 131,252 shares of the company's stock, valued at approximateOctober 22, 2024 | marketbeat.comCybin (NYSE:CYBN) Trading Down 7.4% - Here's What HappenedCybin (NYSE:CYBN) Stock Price Down 7.4% - Here's WhyOctober 21, 2024 | marketbeat.comCybin (NYSE:CYBN) Trading 9.7% Higher - Should You Buy?Cybin (NYSE:CYBN) Stock Price Up 9.7% - Still a Buy?October 18, 2024 | marketbeat.comCybin (NYSE:CYBN) Shares Gap Down - What's Next?Cybin (NYSE:CYBN) Shares Gap Down - Time to Sell?October 14, 2024 | marketbeat.comCybin (NYSE:CYBN) Trading Up 5.4% - Here's WhyCybin (NYSE:CYBN) Trading 5.4% Higher - Still a Buy?October 10, 2024 | marketbeat.comWater Tower Research Publishes Initiation of Coverage Report on Cybin, Inc., “A Leader in Novel Neuropsychiatry Therapeutics”September 27, 2024 | globenewswire.comStrong Buy Rating for Cybin Inc. on Promising Clinical Advances and Strategic Management PositioningSeptember 24, 2024 | markets.businessinsider.comCybin to Participate in the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry SummitSeptember 24, 2024 | finance.yahoo.comCybin (NYSE:CYBN) Sees Large Volume IncreaseCybin (NYSE:CYBN) Sees Strong Trading VolumeSeptember 23, 2024 | marketbeat.comCybin (NYSEAMERICAN:CYBN) Sees Strong Trading VolumeCybin (NYSEAMERICAN:CYBN) Sees Unusually-High Trading VolumeSeptember 23, 2024 | marketbeat.comCanaccord Genuity Group Lowers Cybin (NYSE:CYBN) Price Target to $96.00Canaccord Genuity Group reduced their target price on Cybin from $114.00 to $96.00 and set a "buy" rating on the stock in a report on Monday.September 23, 2024 | marketbeat.comCybin Provides Corporate Update on Upcoming Clinical MilestonesSeptember 19, 2024 | businesswire.comCybin Announces Completion of Previously Announced Share ConsolidationSeptember 19, 2024 | businesswire.comUpcoming Stock Splits This Week (September 16 to September 20) – Stay InvestedSeptember 16, 2024 | msn.comInvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) CEO to Participate at the H.C. Wainwright 26th Annual Global Investment ConferenceSeptember 4, 2024 | msn.comShort Interest in Cybin Inc. (NYSEAMERICAN:CYBN) Grows By 17.0%Cybin Inc. (NYSEAMERICAN:CYBN - Get Free Report) saw a significant increase in short interest during the month of August. As of August 15th, there was short interest totalling 14,900,000 shares, an increase of 17.0% from the July 31st total of 12,740,000 shares. Currently, 2.1% of the company's shares are sold short. Based on an average trading volume of 4,880,000 shares, the days-to-cover ratio is presently 3.1 days.September 2, 2024 | marketbeat.comCybin Inc. (CYBN.NE)September 1, 2024 | finance.yahoo.comInvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Reports on Annual and Special Meeting of Shareholders, Share ConsolidationAugust 28, 2024 | msn.comEquities Analysts Offer Predictions for Cybin Inc.'s Q2 2025 Earnings (NYSE:CYBN)Cybin Inc. (NYSE:CYBN - Free Report) - Investment analysts at HC Wainwright issued their Q2 2025 earnings estimates for shares of Cybin in a report issued on Friday, August 23rd. HC Wainwright analyst P. Trucchio forecasts that the company will earn ($0.01) per share for the quarter. HC WainwrighAugust 26, 2024 | marketbeat.comCybin’s Promising Psychedelic Treatments Bolster Buy Rating and $5 Price TargetAugust 23, 2024 | markets.businessinsider.comCybin's (CYBN) "Buy" Rating Reaffirmed at HC WainwrightHC Wainwright reissued a "buy" rating and issued a $5.00 price target on shares of Cybin in a report on Friday.August 23, 2024 | marketbeat.comBloom Burton Weighs in on Cybin Inc.'s FY2025 Earnings (NYSE:CYBN)Cybin Inc. (NYSE:CYBN - Free Report) - Equities research analysts at Bloom Burton lowered their FY2025 earnings estimates for shares of Cybin in a research report issued to clients and investors on Monday, August 12th. Bloom Burton analyst D. Martin now anticipates that the company will post earnAugust 14, 2024 | marketbeat.comCybin (NYSEAMERICAN:CYBN) Trading 2.3% Higher Cybin (NYSEAMERICAN:CYBN) Stock Price Up 2.3%August 9, 2024 | marketbeat.comEquities Analysts Set Expectations for Cybin Inc.'s FY2029 Earnings (NYSE:CYBN)Cybin Inc. (NYSE:CYBN - Free Report) - Equities research analysts at HC Wainwright cut their FY2029 earnings per share (EPS) estimates for Cybin in a report released on Wednesday, July 31st. HC Wainwright analyst P. Trucchio now forecasts that the company will earn $0.25 per share for the year, dAugust 2, 2024 | marketbeat.comCybin Inc Ordinary Shares CYBNAugust 1, 2024 | morningstar.com3 Biotech Stocks That Could Make Your Summer UnforgettableJuly 30, 2024 | investorplace.comCybin Inc. (NYSEAMERICAN:CYBN) Sees Significant Drop in Short InterestCybin Inc. (NYSEAMERICAN:CYBN - Get Free Report) was the recipient of a significant decrease in short interest during the month of June. As of June 15th, there was short interest totalling 20,550,000 shares, a decrease of 10.6% from the May 31st total of 22,990,000 shares. Based on an average daily volume of 4,040,000 shares, the short-interest ratio is presently 5.1 days. Currently, 3.0% of the company's stock are sold short.July 3, 2024 | marketbeat.com3 Psychedelic Stocks to Buy on the Dip: Summer 2024July 2, 2024 | investorplace.comCybin Reports Fiscal Year 2024 Financial Results and Recent Business HighlightsJune 26, 2024 | businesswire.com Get Cybin News Delivered to You Automatically Sign up to receive the latest news and ratings for CYBN and its competitors with MarketBeat's FREE daily newsletter. Email Address Watch this before it gets removed (Ad)If you missed it, my emergency election broadcast is now available - but will be removed soon Click here to watch it now. CYBN Media Mentions By Week CYBN Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CYBN News Sentiment▼0.170.45▲Average Medical News Sentiment CYBN News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CYBN Articles This Week▼131▲CYBN Articles Average Week Get Cybin News Delivered to You Automatically Sign up to receive the latest news and ratings for CYBN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies NUVB News Today ETNB News Today TYRA News Today RAPP News Today RLAY News Today EOLS News Today PLRX News Today CRON News Today PRTA News Today REPL News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NYSE:CYBN) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cybin Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cybin With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
